South Korea's Biostar Stem Cell Research Institute, which is jointly operated by Nature Cell Co. Ltd. and sister firm R Bio, has filed an IND to begin a domestic Phase III study for JointStem, its stem cell therapy for degenerative osteoarthritis (OA), after national regulatory authorities rejected an earlier filing seeking conditional approval of the therapy.
Nature Cell recently filed an objection to the Central Pharmaceutical Affairs Council's decision and is seeking the conditional approval again,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?